Top Digital Therapeutics Companies

The digital therapeutics market is forecasted to grow at a CAGR of 26.3% during the forecast period of 2025 - 2032.

As the prevalence of chronic disease continues to rise throughout the world, with conditions such as diabetes, cancer, and cardiovascular disease, the demand for digital therapeutics is ramping up based on the need for effective, evidence-based methods to manage and prevent chronic conditions.

The increased adoption of smart phones globally allows the widespread use of mobile health apps, cloud-based platforms and digital therapies, driving growth through the ease and personalization of health care delivery.

Digital therapeutics incorporate mobile apps, AI, machine learning, cloud-based platforms, wearables, big data analytics, and internet connectivity to provide evidence-based health care interventions and monitor outcomes.

Main treatment applications are diabetes, cardiovascular diseases, central nervous system disorders, respiratory diseases, gastrointestinal disorders, musculoskeletal disorders, medication adherence, substance use disorder, and rehabilitation therapy.

Preventive digital therapeutics are rapidly expanding in relation to obesity, prediabetes, and lifestyle applications due to increasing awareness of chronic diseases, increased chronic disease burden, and regulatory backing to improve early detection/prevention of disease.

AI is applied across therapeutic areas to enable personalized treatment trajectories and analyze patient health data, and improve clinical decision making, to improve the effectiveness of therapy and patient outcomes. In digital therapeutics, AI continues to facilitate real-time monitoring, diagnostics, and treatment.

B2B is generally looking to engage with providers, payers, and/or pharma for implementation and reimbursement. B2C is more focused on engaging directly with patients to create user-friendly experiences and allowing for more comfortable implementation and interests advancing self-management, accessibility. 

For the digital therapeutics market, there are subscription models, single purchase or annual license models, and outcome/value-based models that will be aligned to level of therapeutic success and patient improvement.

Cyber security challenges with in patient data privacy risks, and lack of regulations have limited the use of digital therapeutics because patients and providers are concerned about whether sensitive medical records will be safe.

Global Digital Therapeutics Market size was valued at USD 4.01 Billion in 2024 and is poised to grow from USD 4.68 Billion in 2025 to USD 15.99 Billion by 2033, growing at a CAGR of 16.61% during the forecast period (2026–2033).

The digital therapeutics is a dynamic and fragmented market. It consists of many players in digital therapeutics industry who offer a wide range of products, like mobile software and devices. Pear Therapeutics, Inc, is dominating the market with a strong line of software. The growing sales of reSET & reSET-O in the U.S. are supporting its strong market share. Furthermore, the increasing investments in research and development of digital therapeutics products is also contributing towards the expansion of the market globally. 'Noom, Inc ', 'Teladoc Health, Inc. ', 'Omada Health, Inc. ', 'WellDoc, Inc ', 'Biofourmis ', 'Better Therapeutics, Inc ', 'Amalgm Rx ', 'CogniFit Inc ', 'Headspace Health ', 'Propeller Health ', 'Virta Health Corp ', '2Morrow, Inc. ', 'Realizedcare (via XRHealth) ', 'Canary Health ', 'Twill Inc. ', 'Click Therapeutics, Inc. ', 'Akili, Inc. ', 'Cognoa, Inc ', 'Wellthy Therapeutics Pvt. Ltd. ', 'Kaia Health'

The demand for therapeutics software and devices is increasing because of the management and treatment of chronic diseases globally. Furthermore, the incidences of chronic conditions, like type 1 diabetes & type 2 diabetes, cancers, Alzheimer’s diseases, obesity, and gastrointestinal disorders are also increasing. This is especially true in emerging economies, which is propelling the demand for this software during the forecast period.

Is North America Leading the Digital Therapeutics Market Due to Innovation and Chronic Disease Burden?   North America contributed the most with around 41% of worldwide revenue. This is due to a variety of reasons, including increased use of digital health devices and beneficial reimbursement scenarios that emphasize improving quality of life through improved tracking and diagnostics. The market is likely to be driven by the frequency of chronic diseases and the increase in the aging population in the region. Furthermore, the region is a hub for many solutions providers for digital therapeutics that again drive the region's market growth. Proteus Digital Health, Inc., Omada Health, Inc., WellDoc, Inc., and Livongo Health, Inc. are some of the leading companies in this field. Most of these corporations are located in the United States, which contributes to their local dominance.